Advanced Genomics APAC

Advanced Genomics APAC Announces Partnership with 3BIGS CO., LTD. to Expand Cancer Genomic Testing Services Across Asia-Pacific 🌏🫱🏻🫲🏻 We are excited to announce our partnership with 3BIGS CO., LTD., marking a significant milestone in advancing cancer genomic testing services in the #APAC region! Through this collaboration, Advanced Genomics APAC will integrate Nonacus #GALEAS technologies with 3BIGS CO., LTD.’ expertise in 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝘀 and 𝗱𝗮𝘁𝗮 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀📊, delivering 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 (𝗖𝗚𝗣) solutions for cancer therapy and hereditary cancer tailored to meet regional needs🎗️ With over 🚨𝟵.𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗻𝗲𝘄 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗮𝘀𝗲𝘀 𝗮𝗻𝗻𝘂𝗮𝗹𝗹𝘆 in the region and 📈𝗿𝗶𝘀𝗶𝗻𝗴 𝗶𝗻𝗰𝗶𝗱𝗲𝗻𝗰𝗲 𝗿𝗮𝘁𝗲𝘀, the partnership aims to address the urgent demand for scalable and cost-effective diagnostic solutions. By developing 𝗰𝗮𝗻𝗰𝗲𝗿 𝗴𝗲𝗻𝗲 𝗽𝗮𝗻𝗲𝗹𝘀 and 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲𝗱 𝗯𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝘀 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲𝘀, we aim to empower clinicians and researchers with reliable and actionable insights, facilitating precision medicine and personalized treatment strategies💡 Together, Advanced Genomics APAC and 3BIGS CO., LTD. are committed to driving innovation in cancer diagnostics, ensuring better outcomes and improved quality of life for patients across Asia-Pacific. This collaboration sets the stage for transformative healthcare solutions and a healthier tomorrow❤️🩹 𝙍𝙚𝙖𝙙 𝙈𝙤𝙧𝙚📖 https://lnkd.in/gX3X2nmu #AdvancedGenomicsAPAC #Nonacus #3BIGS #Partnership #AsiaPacific #NGS #Cancer #Panel #GenomicTesting #Healthcare #Diagnostics #AI #Biotech #Bioinformatics #PersonalizedMedicine

Transform your way of monitoring bladder health with 𝗚𝗔𝗟𝗘𝗔𝗦 𝗕𝗹𝗮𝗱𝗱𝗲𝗿!❤️🩹 𝐖𝐚𝐭𝐜𝐡 𝐡𝐞𝐫𝐞📽️: https://lnkd.in/gu_4hk47 #AdvancedGenomicsAPAC #Nonacus #GALEAS #Bladder #Biotech #Healthcare #Genetics #Detect #Report #Monitor #EarlyDetection #NonInvasive #GeneticTesting #Biomarker #NGS #Panel #BladderCancer #Cancer

🌱Together We Grow, Together We Achieve At Advanced Genomics APAC, we believe that a strong team is the foundation to success. Our recent team-building day brought us together to deepen our teamwork, spark creativity, and refine our strategic vision. We took the time to deepen our bond and better understand each other’s personal and working preferences. This connection helped us feel more aligned and motivated, fueling us to work toward our shared goals 🧩 After all the insightful activities, we enjoyed some well-deserved downtime —bonding over arcade games, laughter, and relaxation. It was the perfect way to strengthen our connections beyond office walls and celebrate the supportive culture we are building together💪✨ #AdvancedGenomicsAPAC #TeamBuilding #Teamwork #InnovationThroughCollaboration

White November: Raising Awareness for Lung Cancer🫁🎗️ Lung cancer is the leading cause of cancer globally, with approximately 𝟮.𝟰𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗻𝗲𝘄 𝗰𝗮𝘀𝗲𝘀 reported in 2022 and accounting for the highest mortality rates among both men and women. 𝗟𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 is often diagnosed at advanced stages, making treatment options limited. While multiple factors contribute to its onset, 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗽𝗿𝗲𝗱𝗶𝘀𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 plays a significant role, highlighting the vitality of understanding family history. Screening high-risk individuals can facilitate early detection and significantly improve survival rates (WHO, 2023) 🔍 🧬𝗚𝗔𝗟𝗘𝗔𝗦™ 𝗛𝗲𝗿𝗲𝗱𝗶𝘁𝗮𝗿𝘆 𝗣𝗹𝘂𝘀 is a clinically-validated NGS panel that detects 𝗴𝗲𝗿𝗺𝗹𝗶𝗻𝗲 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀 associated with 𝗵𝗲𝗿𝗲𝗱𝗶𝘁𝗮𝗿𝘆 𝗰𝗮𝗻𝗰𝗲𝗿𝘀. It offers genetic insights to guide proactive health decisions for 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗶𝘀𝗸 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁. 💡𝗪𝗵𝘆 𝗚𝗔𝗟𝗘𝗔𝗦™ 𝗛𝗲𝗿𝗲𝗱𝗶𝘁𝗮𝗿𝘆 𝗣𝗹𝘂𝘀? ✅𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗚𝗲𝗻𝗲 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 Targets germline mutations in 𝟭𝟰𝟲 𝗴𝗲𝗻𝗲𝘀 associated with hereditary cancers, including key genes linked to lung cancer such as STK11, EGFR, and TP53. ✅ 𝗦𝗶𝗻𝗴𝗹𝗲 𝗪𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗳𝗼𝗿 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗧𝘆𝗽𝗲𝘀 Allows a streamlined workflow that can analyze various sample types (e.g., blood or saliva) and confidently call all variants, including CNVs in genes relevant to hereditary cancer ✅ 𝗛𝗶𝗴𝗵 𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 & 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆 𝟭𝟬𝟬% sensitivity and 𝟵𝟯.𝟱% specificity, ensuring accurate detection of genetic variants that may predispose individuals to cancer ✅ 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗲𝗱 𝗕𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝘀 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗚𝗔𝗟𝗘𝗔𝗦™ 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 enhances the accuracy of variant calling across all genetic alterations ✅ 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 Utilizing our comprehensive report, healthcare providers can tailor a more personalized prevention plans 𝘌𝘢𝘳𝘭𝘺 𝘥𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯 𝘮𝘢𝘬𝘦𝘴 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦. In this #LungCancerAwarenessMonth, Advanced Genomics APAC stands in with everyone affected by lung cancer. Our support goes to the dedicated organizations leading in lung and respiratory health research and advocacy: the International Association for the Study of Lung Cancer, International Union Against Tuberculosis and Lung Disease (The Union), Australian and New Zealand Society of Respiratory Science (ANZSRS), The Thoracic Society of Australia and New Zealand (TSANZ), Lung Foundation Australia, as well as our fellow biotech and healthcare providers. Let's continue this journey to empower individuals for early detection and better healthcare management, together with Advanced Genomics APAC!✨ #AdvancedGenomicsAPAC #Nonacus #Biotech #Genetics #Hereditary #Cancer #GALEAS #LungCancer #Awareness #November #Diagnostics #GenomicTesting #Healthcare  #PersonalizedMedicine #EarlyDetection

Advanced Genomics APAC and Compass Bioinformatics Collaborate to Advance Rare Disease Diagnostics and Cancer Testing!📄🤝🏻 The announcement of our strategic partnership with Compass Bioinformatics marks the beginning of a collaborative effort to expand the application of 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 (𝗡𝗚𝗦) technology in the field of 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 and 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, targeting key markets across Japan, South Korea, Southeast Asia, and the Australia-New Zealand region. 🏥With over 𝟭𝟬,𝟬𝟬𝟬 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 affecting lives worldwide, patients often endure 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝘀𝗶𝘅 𝘆𝗲𝗮𝗿𝘀 before receiving a diagnosis, with 𝗼𝘃𝗲𝗿 𝟴𝟬% of these conditions being 𝗵𝗲𝗿𝗲𝗱𝗶𝘁𝗮𝗿𝘆. This highlights the urgent need for efficient and effective diagnostic solutions. Through this collaboration, Advanced Genomics APAC will leverage a flagship product, 𝗖𝗲𝗹𝗹𝟯™ 𝗧𝗮𝗿𝗴𝗲𝘁: 𝗡𝗲𝘅𝗼𝗺𝗲 𝗣𝗮𝗻𝗲𝗹, renowned for its capability to confidently identify SNVs, INDELs, and CNVs with high recall and precision from as little as 1 ng of DNA. This capability unlocks robust insights regardless of sample volume limitations. Additionally, the product has been specifically optimized for hereditary rare diseases, allowing efficacy in detection of disease-specific gene variants 🧬 Compass Bioinformatics is a renowned leading company, focusing on genomics analysis software development which has been empowering the healthcare providers. Through the partnership, Compass Bioinformatics will introduce 𝗜𝗻𝗵𝗲𝗿𝗶𝗡𝗲𝘅𝘁® which has shown outstanding diagnosis capability of over 𝟯,𝟱𝟬𝟬 𝗰𝗮𝘀𝗲𝘀 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, registered as Class I software medical device from the USA FDA as well as quality certifications like Taiwan's TFDA and international ISO 13485, ensuring its reliability. This partnership aims to deliver a comprehensive solution—from library construction to data analysis—enabling healthcare providers to offer a timely and accurate diagnosis alongside personalized treatment plans 💻 This collaboration lays a strong foundation for a big leap in advancing precision medicine and improving the quality of life for patients. United, we are paving the way for a healthier tomorrow ❤️🩹 #AdvancedGenomicsAPAC #Nonacus #CompassBioinformatics #Partnership #Cell3 #Nexome #Target #Panel #InheriNext #Software #Analysis #Biotech #NGS #Diagnostics #GenomicTesting #Healthcare  #Hereditary #RareDisease #Cancer #PersonalizedMedicine #Bioinformatics

🚀Marking a New Milestone on Biotech Journey Congratulations to our Chairman & Managing Director, Andy Chang, for being named among the 𝘁𝗼𝗽 𝟭𝟬 in the 𝟮𝟬𝟮𝟰 𝗕𝗲𝘀𝘁 𝗕𝗶𝗼 𝗦𝘁𝗮𝗿𝘁𝘂𝗽 𝗖𝗘𝗢 𝗔𝘄𝗮𝗿𝗱𝘀 by Global Bio & Investment Monthly! Andy Shared his journey in the biotech industry—a path defined by resilience, bold decision-making, and a commitment to advancing healthcare. With his invaluable experience and visionary leadership, Andy is on a mission to drive impactful innovations in precision medicine and genomics throughout the Asia-Pacific region, particularly Taiwan. His passion continues to motivate our team at Advanced Genomics APAC as we strive to enhance healthcare for all. With this milestone, we are inspired to keep pushing the boundaries of what is possible—embracing innovation, impact, and purpose. A heartfelt thank you to Global Bio & Investment Monthly for the honor. #AdvancedGenomicsAPAC #Nonacus #Biotech

Advanced Genomics APAC Partners with Pangenia Inc to Enhance Bladder Cancer Service in Hong Kong! 📄🤝🏻 We are thrilled to announce our partnership with Pangenia Inc, marked by the signing of an 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 on October 16, 2024. At Advanced Genomics APAC, we are dedicated to 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 by integrating cutting-edge 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 into the clinical landscape. Our mission is to empower healthcare providers🩺 with innovative tools that promote early detection and personalized treatment options for various diseases, particularly cancer. This enables providers to deliver more precise and tailored care to their patients. Pangenia Inc, part of the EC Healthcare, is a leader in molecular diagnostics in Hong Kong. With extensive expertise in 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝘁𝗲𝘀𝘁𝗶𝗻𝗴🔬, Pangenia Inc specializes in various services, including cancer diagnostics, prenatal testing, and hereditary risk assessments. Their commitment to scientific innovation has established them as one of Hong Kong's leading biotech companies. 𝗕𝗹𝗮𝗱𝗱𝗲𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 poses significant challenges in Hong Kong, with rising incidence rates and a lack of awareness in the importance of early detection The current diagnostic landscape faces challenges, including the need for more accessible testing options and timely intervention strategies. Through this partnership, we will utilize 𝗚𝗔𝗟𝗘𝗔𝗦 𝗕𝗹𝗮𝗱𝗱𝗲𝗿 to address these challenges. By combining our innovative testing capabilities with Pangenia Inc’s expertise, we aim to 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗯𝗹𝗮𝗱𝗱𝗲𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗶𝗻 𝗛𝗼𝗻𝗴 𝗞𝗼𝗻𝗴 🇭🇰 Together, we can pave the way for better detection and treatment of bladder cancer!💡 #AdvancedGenomicsAPAC #Nonacus #Pangenia #ECHealthcare #GALEAS #BladderCancer #Cancer #NonInvasive #GenomicTesting #NGS #Diagnostics #EarlyDetection #PersonalizedMedicine #HealthCare

Advanced Genomics APAC and Medcomtech JSC Partner to Deliver Bladder Cancer Service in Vietnam 📄🤝🏻 We are thrilled to announce our partnership with Medcomtech, marked by the signing of a 𝗠𝗲𝗺𝗼𝗿𝗮𝗻𝗱𝘂𝗺 𝗼𝗳 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 on Tuesday, October 1, 2024. 🧬At Advanced Genomics APAC, we are dedicated to advancing healthcare through 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 which empowers healthcare providers to implement personalized treatment strategies, ultimately enhancing patient outcomes. 🔬Our valued partner, Medcomtech JSC shares our vision for advancing healthcare, particularly in Vietnam. They provide 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 solutions, ensuring the highest quality of care, from accurate diagnostics to effective treatment monitoring. Together, we are utilizing 𝗚𝗔𝗟𝗘𝗔𝗦 𝗕𝗹𝗮𝗱𝗱𝗲𝗿 to address bladder cancer, a growing health challenge in 𝗩𝗶𝗲𝘁𝗻𝗮𝗺. Our collaboration aims to transform 𝗯𝗹𝗮𝗱𝗱𝗲𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 services in Vietnam by implementing advanced genomic testing and personalized treatment strategies. By integrating our innovative technologies with Medcomtech JSC's solutions, we aspire to enhance early detection and improve patient outcomes! 【🇻🇳 VN | phiên bản tiếng Việt】 Chúng tôi rất vui mừng thông báo về sự hợp tác với Medcomtech, được đánh dấu bằng việc ký kết Biên bản ghi nhớ vào thứ Ba, ngày 01 tháng 10 năm 2024. 🧬Tại Advanced Genomics APAC, chúng tôi cam kết nâng cao chăm sóc sức khỏe thông qua các giải pháp đổi mới. Chuyên môn của chúng tôi trong Xét nghiệm di truyền giúp các nhà cung cấp dịch vụ y tế thực hiện các chiến lược điều trị cá nhân hóa, từ đó nâng cao kết quả cho bệnh nhân. 🔬 Là đối tác quý giá của chúng tôi, Công ty Cổ phần Medcomtech JSC chia sẻ tầm nhìn về việc cải thiện dịch vụ chăm sóc sức khỏe tại Việt Nam. Họ chuyên cung cấp các giải pháp công nghệ y tế đổi mới, bao gồm thiết bị chẩn đoán tiên tiến và hệ thống xét nghiệm. Cam kết của họ trong việc tích hợp công nghệ tiên tiến vào thực hành lâm sàng đảm bảo rằng bệnh nhân nhận được chất lượng chăm sóc cao nhất, từ chẩn đoán chính xác cho đến theo dõi điều trị hiệu quả. Chúng tôi rất mong chờ được sử dụng Dịch vụ xét nghiệm ung thư bàng quang để giải quyết những thách thức trong chăm sóc ung thư bàng quang tại Việt Nam. Căn bệnh này vẫn là một vấn đề sức khỏe đáng lo ngại trong khu vực, với tỷ lệ mắc bệnh ngày càng tăng và nhu cầu cấp bách về các phương pháp chẩn đoán và điều trị được cải thiện. Sự hợp tác này nhằm mục tiêu biến đổi dịch vụ ung thư bàng quang tại Việt Nam bằng cách triển khai xét nghiệm gen tiên tiến và các chiến lược điều trị cá nhân hóa. Bằng cách tích hợp các công nghệ đổi mới của chúng tôi với giải pháp của Medcomtech JSC, chúng tôi hy vọng nâng cao khả năng phát hiện sớm và cải thiện kết quả cho bệnh nhân. #AdvancedGenomicsAPAC #Nonacus #Medcomtech #GALEAS #BladderCancer #Cancer #NonInvasive #GenomicTesting #NGS #Diagnostics #EarlyDetection #PersonalizedMedicine #HealthCare

Advancing Cancer Healthcare for All: Advanced Genomics APAC Joins Forces in the 「癌飛 (CancerFree)」 Initiative! 🎗️ Today, September 30, 2024, Advanced Genomics APAC, alongside CancerFree Biotech and Genomics BioSci & Tech Co Ltd, gathered for a meaningful public welfare sharing session. During this event, we shared our vision and mission for the「癌飛 (CancerFree)」initiative, a collaborative effort aimed at democratizing cancer management. Cancer affects not just individuals but entire families, and the statistics are alarming⚠️ For over 42 consecutive years, cancer has been the leading cause of death in Taiwan, accounting for more than 53,000 mortalities annually. The「癌飛 (CancerFree)」initiative is dedicated to providing essential support for cancer patients, particularly those from underserved communities, because we believe that cancer care should be accessible to all, regardless of economic status or circumstances. 🧬 Commited to this initiative, 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗔𝗣𝗔𝗖 proudly contribute by offering GALEAS platform, empowering healthcare providers with insights for personalized cancer care tailored to individual patient needs. 🔬 Our partners, 𝗖𝗮𝗻𝗰𝗲𝗿𝗙𝗿𝗲𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 and 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗕𝗶𝗼𝗦𝗰𝗶 & 𝗧𝗲𝗰𝗵 , are committed to delivering services, including personalized cancer drug testing and advanced genetic profiling. We envision a future where "𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗡𝗼𝗻-𝗜𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲" becomes a reality for everyone. Our aim is to break through barriers and foster hope, ensuring that every patient—regardless of their economic background—has the opportunity to access personalized, effective cancer care. Let’s soar to new heights in cancer care, together with Advanced Genomics APAC!🏥✨ #AdvancedGenomicsAPAC #Nonacus #GenomicsBioSciAndTech #CancerFreeBiotech #CancerFree #癌飛 #Biotech #NonInvasive #GenomicTesting #GALEAS #CancerCare #HealthCare #PersonalizedMedicine #CancerAwareness

💡From Concept to Strategy: Business Development Brainstorming at Advanced Genomics APAC Recently at Advanced Genomics APAC, we had an exciting brainstorming session focused on refining our business and marketing plan. We explored innovative strategies to enhance brand awareness and effectively reach our target. Part of the session involved investigating and identifying our current partners, ensuring mutual alignment and exploring their strengths. We also discussed collaboration opportunities with potential partners across the APAC region, broadening our scope for future growth. We are eager for what lies ahead and open to new partnerships. Let’s connect, collaborate and drive healthcare innovation together with Advanced Genomics APAC! 🧬 #AdvancedGenomicsAPAC #Nonacus  #NonInvasive #GenomicTesting #NextGenerationSequencing #NGS